

GU Interventions

Gerant Rivera-Sanfeliz, MD
Professor of Radiology



UC San Diego
MEDICAL CENTER

History of GU Interventions

- Percutaneous nephrostomy - 1955
- Percutaneous stone removal - 1976
- Ureteral stent placement - late 70's
- ESWL - 1982
- Percutaneous tumor ablation - late 90's



GU Interventions

- Percutaneous nephrostomy (PCN)
- Percutaneous nephrostolithotomy (PNL)
- Percutaneous ureteral interventions
- Percutaneous collection drainage
- Percutaneous biopsy
- Percutaneous tumor ablation




PCN - Indications

- Relief of obstruction
- Treat urinary leak/fistula
- Symptomatic stone disease
- Complex urinary tract infections
- Ureteral interventions
- Diagnostic and therapeutic endourologic interventions




PCN – Avascular Plane



PCN – Calyceal Entry



PCN – Injection of Air




PCN – Adjacent Organs




PCN – Access

- Lower calyceal group
 - best suited for simple drainage
 - usually via a posterolateral approach below the 12th rib



PCN – Access

- Middle calyceal group
 - optimal access when ureteral manipulation is expected or targeted PCN




PCN – Access

- Upper calyceal group
 - usually reserved for complex manipulations (Staghorn calculus)
 - increased risk for bleeding and pleural transgression when above 11th rib




PCN - Procedure

- Prone position, IV sedation
- **Guidance** - ultrasound/fluorosc
- **Access** - use of 0.018-0.035 conversion system



PCN - Procedure

- Sample of urine for culture
- Do not **overdistend** a potentially infected system
- Delivery of 8-10F Cope loop catheter



PCN - Complications

- Hematuria

- progressively decreases during the first 24 - 48 hrs

- major bleeding reported in 1-2% of the cases

PCN - Complications

- Hematuria management
 - catheter upsizing
 - catheter clamping
 - tamponade balloon catheter (large tracts)
 - blood transfusions
 - renal arteriography/transcatheter embolization





UC San Diego
MEDICAL CENTER




UC San Diego
MEDICAL CENTER

PCN - Complications

- Sepsis - 1%
- Inadvertent adjacent organ injury
- Catheter dislodgement/blockage





Potential Pitfall: XGP


Xanthogranulomatous Pyelonephritis

- 5th -7th decade, **Female** > Male
- Diffuse (90%), Segmental
- Plasma cells + lipid-laden macrophages (xanthoma cells)
- Anemia (70%), **elevated LFT's** (25%), diabetes (10%)
- Enlarged, malfunctioning kidney with central obstructing calculus
- DDx: **hydronephrosis**, avascular tumor



Pediatric Nephrostomy

- Micropuncture vs. modified two-step
- Modified favored in dilated systems (UPJ)
- Micropuncture favored for non-dilatation, distal obstruction, coagulopathy



Koral K et al. JVIR 2003; 14:113-116



Stone Therapy


- Most calculi < 8mm will pass
- Open surgical techniques are seldom used
- ESWL remains the primary modality for stones below 2 -3 cm
- ESWL limitations

ESWL - Limitations

- Large stones > 3 cm
- Stone in lower calyx
- Impacted, large ureteral stones
- Anatomic abnormalities preventing stone passage
- Staghorn calculi – produce large fragment burden, risk for sepsis
- Pregnant or pediatric patients



PNL – Tract Selection




PNL - Results

- Success - 95%
- May require more than one intervention or tracts
- Complications higher than PCN, occur in 4-8%
- Most common complications include perforation of the renal pelvis and bleeding



Decompression In Stone Disease

- Obstruction, infection, renal deterioration, intractable pain
- PCN vs. DJ
- UCSD favors PCN



PCN vs. Ureteral Stent

- Prospective, randomized, stone hydro
- 40 patients: 20 PCN, 20 DJ
- Tech success: 100% PCN, 80% DJ
- Failure of DJ in prox stone, age > 60
- PCN shorter indwelling time (p= 0.043)
- Clinical course/QOL: Tendency in favor of PCN
- No mention of complications rates

Mokhmalji H, et al. Urology 2001; 165:1088-1092

Percutaneous Renal Access

Additional Indications

- Endourologic management of upper tract TCC including **biopsy**
- Chemolysis for stone therapy
- Management of fungal disease
- Endopyelotomy for UPJ obstruction



Percutaneous Ureteral Interventions

- Ureteral **stent** placement
- Ureteral **stricture** dilatation
- Ureteral **occlusion**



40 y/o woman with flank pain and hydronephrosis



Ureteral Stent - Indications

- Similar to PCN – leak, obstruction, stone, fistula
- As a scaffold following balloon dilatation, endopyelotomy, or PNL
- Intra-operative ureteral identification in pelvic surgery




Ureteral Stent – Good or Bad?

- Finney and Hepperlen (1975)
- Urine flows through and around stents
- Ideal material not yet available
- Issues with infection and encrustation



Ureteral Stent - Types

- Double pigtail stents - internal drainage
- Nephroureteral stents - both internal and external drainage



Issues with “Double J”

- Advantages:

- decreased rate of infection
- better patient acceptance(maybe)

- Disadvantages:

- difficulty in assessing for occlusion
- require exchange every 3 - 6 months



Ureteral Stent - QOL

- 85 consecutive patients (73%)
- 78% bothersome urinary symptoms
- > 80% with pain affecting daily activities
- 32% sexual dysfunction
- 58% reduced work capacity

Joshi HB, et al. J Urol 2003; 169:1065-1069

Ureteral Stent - Biomaterials

- Polyurethane, silicone, Silitek, C-Flex, Percuflex and metal
- PU: highly versatile and inexpensive, > urothelial ulceration and erosion
- Silicone: better tissue compatibility 2^{ry} to its nontoxic and inert nature



Ureteral Stent - Biomaterials

- Encrustation due to rx of magnesium ammonium phosphate to urease + bacteria (**Abber JC, Kahn RI. J Urol 1983; 130: 763**)
- Coatings: Hydrogel




Ureteral Stent – What's New?

Coatings

- **Goals:** facilitate delivery, reduce encrustation
- **Materials:**
 - Polyvinylpyrrolidone
 - Phosphorylcholine
 - Heparin
 - Oxalate degrading enzymes
 - Silver nitrate and ofloxacin


Multiple Double J's

- Failed single stent
- Extrinsic compression
- Malignancy



Liu JS, et al. J Urol
1998; 159:179-181

Fromer DI, et al. Urology
2002; 59:594-596



Ureteral Stent - Placement

- A middle calyceal approach is preferred
- 6-8F, 22-26cm
- Smaller stents for stones, larger for malignancy and following dilatation
- Careful assessment of intraluminal location both in the ureter and bladder



Ureteral Stent - Complications

- Urinary symptoms: pain, dysuria, hematuria, incontinence, bladder irritability
- Encrustation
- Infection
- Migration, fragmentation



Ureteral Stricture Dilatation


- Balloon dilatation has **modest results** (50%)
- Most effective in **short, recent onset and proximal strictures**
- Malignant, irradiated, ischemic, inflammatory and anastomotic strictures **respond less favorably**



Percutaneous Collection Drainage

- Renal and peri-renal abscess
- Urinoma
- Lymphocele





Renal/Peri-renal Abscess

- Predisposing factors:
 - Diabetes
 - Urinary calculi
 - Obstruction
 - Debilitated
- Mortality as high as 50%
- Drain left in place until output decreases to 5-10ml in 24hrs





3 month F/U

Urinoma

- Etiologies:
 - iatrogenic
 - traumatic
 - obstructive
 - tumoral
 - inflammatory
 - renal tx
- Management usually includes percutaneous drainage plus PCN and ureteral stent placement



Lymphocele

- Common as a complication following lymph node dissection and renal transplantation
- May be symptomatic when infected or by extrinsic compression to adjacent structures
- Simple drainage yields unsatisfactory results




Lymphocele

- Sclerosing agents : ethanol, iodopovidone and tetracycline
- Mixed results
- Rule -out communication to bowel or urinary tract
- Half of cavity volume instilled with sclerosant with dwell time of 30-60 minutes
- Complication: 1) cavity superinfection
2) communication injury



Percutaneous Renal/Adrenal Biopsy

- **Mets, lymphoma, limited kidneys**
- **RCC** - core for genetics, expectant management for low grade tumors, Cryo
- Transhepatic route for adrenal



Renal Tumor Ablation

- Parenchymal sparing surgery (**Herring J Urol 2001**)
- Small, incidentally discovered renal tumors
- **Radiofrequency ablation, cryoablation, interstitial laser and high intensity ultrasound** have been used
- Percutaneous or laparoscopic technique



Renal Cryo


Nonsurgical candidates

- solitary kd
- mets
- multiple RCC' s





Small < 3cm

Peripheral

- anterior: lap
- posterior: perc







Preprocedural CT




2.4 Endocare cryoprobes – placed probes at a superior and inferior locations


















Two Freeze-thaw cycles

























Patient Selection

Nephron sparing surgery:

Partial nephrectomy recommended for all T1 tumors < 7 cm (as long as margins can be removed and expected morbidity is acceptable)



Cryoablation

- Not surgical candidate
- Likely to develop numerous tumors (VHL/elderly)
- Ideal Tumor: small (< 4 cm), partially exophytic, posterior
 - Central and Larger tumors: higher rate of tx failure and hemorrhage
- Relative contraindications: younger patient age, large tumors, hilar/centrally located tumors, and cystic neoplasms




Technique

- Probes should be positioned 1 cm from the tumor margin and 1–2 cm from each other
- The use of *multiple probes* creates a **synergistic effect** that results in the formation of even more ice
- **Two** 10 minute **freezes** (argon) cycle separated by a 8 minute passive **thawing** (helium) cycle
- Can perform open, lap, or perc
 - Lap: anterior location, larger cryoprobes, surgical hemostasis
 - Perc: posterior location, CT/US with accurate depiction of ablative zone, less invasive, better M&M



How does it work?

- Synergistic effect
 - intracellular and extracellular ice crystals are directly cytotoxic and lead to cell dehydration and rupture
 - When thawed, there is microvascular occlusion with cell hypoxia resulting in indirect ischemic injury
- Cell death is time and temperature dependent,



Imaging Follow-up

- Lack of enhancement and decrease in size are reliable indicators of successful cryoablation
 - CT 3/6/12 months, yearly afterwards
 - Benign peripheral contrast enhancement may persist for several months
 - Nodular, irregular or crescent shaped enhancement is suggestive of residual tumor
 - Residual viable tumor is typically T2 hyperintense and enhances.
 - Doubtful cases – targeted biopsy



Complications

- Hemorrhage
- Urine leak
- UTI
- Pain
- Transient elevation of creatinine
- Incomplete treatment

Buy et al. Percutaneous Renal Cryoablation: Prospective Experience Treating 120 Consecutive Tumors. [AJR Am J Roentgenol](#). 2013 Dec;201(6):1353-61. doi: 10.2214/AJR.13.11084

Midterm follow-up study evaluating safety/efficacy of cryoablation

- Prospective nonrandomized – **95 patients** (nonsurgical candidates)
- Mean followup: **28 months** (range 6-63 months)
- Mean tumor size: **26 mm** (range 10-68 mm)
- 91 treated with CT guidance, 29 with MRI guidance
- **Technical success rate 94%** (two tumors required second cryoablation due to recurrence/residual tumor)
- **Complication rate 7.3%**
 - Bleeding
- Survival: **After 12 months – 96.7% and disease free rate 96.4%**
- Renal function was unchanged even in those with only 1 kidney
- Limitations of study: short follow-up, assessment of tumor ablation based on radiology without pathologic correlation



Cryoablation vs RFA

- Cryo

- Less painful
- Monitoring ablative zone
- Bleeding

- RFA

- Less bleeding
- Ureteral injury
- Higher recurrence, especially central

